NAV
$33.63
AUM
$67.4M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.63
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +18.44% | +15.61% | +16.18% | +57.01% | +19.46% | +6.18% |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | GILD | Gilead Sciences Inc | 7.40% |
| 2 | VRTX | Vertex Pharmaceuticals Inc | 7.38% |
| 3 | AMGN | Amgen Inc | 7.11% |
| 4 | REGN | Regeneron Pharmaceuticals Inc | 5.09% |
| 5 | ALNY | Alnylam Pharmaceuticals Inc | 3.19% |
| 6 | RVMD | Revolution Medicines Inc Ordinary Shares | 2.49% |
| 7 | BIIB | Biogen Inc | 2.29% |
| 8 | ILMN | Illumina Inc | 1.98% |
| 9 | UTHR | United Therapeutics Corp | 1.94% |
| 10 | RPRX | Royalty Pharma PLC Class A | 1.90% |
The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
Inception Date: 2021-06-11